Early results from the University of Oxford and AstraZeneca coronavirus vaccine trial showed “robust” responses from the immune system, according to the pharmaceutical firm.
“The COVID-19 AZD1222 vaccine showed robust immune responses in all participants in the phase I / II trial,” AstraZeneca said in an emailed statement.
About 1,077 people participated in the AZD1222 study, which is also known as ChAdOx1 nCoV-19. About half of the participants received the experimental vaccine.
TESTING CORONAVIRUS VACCINES IN THE UK IS ‘PROGRESSING VERY WELL’, RECRUITING CHILDREN AND OLDER ADULTS
In the research, the scientists said they found that their experimental COVID-19 vaccine produced a dual immune response in people ages 18 to 55. Dr. Adrian Hill, director of the Jenner Institute at Oxford University, said the vaccine candidate produced neutralizing antibodies. .
In this photo released by the University of Oxford, a doctor takes blood samples for use in a coronavirus vaccine trial in Oxford, England, Thursday, June 25, 2020 – file photo.
(John Cairns, University of Oxford via AP)
In addition, the vaccine also causes a reaction in the body’s T cells, which help fight the coronavirus.
“We are seeing a good immune response in almost everyone,” said Dr. Hill. “What this vaccine does particularly well is to trigger both arms of the immune system.”
Reported side effects from the trial include tiredness, headaches, muscle aches, chills, and fever. No serious side effects were observed.
MORE THAN 100 YEARS BEFORE CORONAVIRUSES, THE SPANISH FLU PANDEMIC SPOKEN THE BALLOON
Further evaluation of the vaccine is underway. “ChAdOx1 nCoV-19 showed an acceptable safety profile and a homologous increase in antibody responses,” the researchers wrote in the study. “These results, along with the induction of both humoral and cellular immune responses, support the large-scale evaluation of this candidate vaccine in an ongoing phase 3 program.”
The research results are published in the medical journal The Lancet.
With 296,364 cases and 45,385 deaths, the United Kingdom is one of the countries most affected by the coronavirus pandemic, according to data compiled by Johns Hopkins University.
AstraZeneca shares were slightly lower in early Monday trading, changing hands at $ 61.02, 0.15 percent.
THE INVESTIGATION VACCINE PROTECTS THE MONKEYS AGAINST COVID-19 PNEUMONIA
Various efforts are underway to develop a coronavirus vaccine worldwide. Scientists at Israel’s Tel Aviv University and the biopharmaceutical company Neovii, for example, recently announced a project to develop a COVID-19 vaccine.
Experts involved in the effort say they are targeting the coronavirus “Achilles’ heel.”
As of Monday morning, more than 14.5 million cases of coronaviruses have been diagnosed worldwide, of which at least 3.7 million are in the U.S., according to Johns Hopkins University. The disease has accounted for at least 606,741 deaths worldwide, including at least 140,541 people in the U.S.
CLICK HERE TO GET THE FOX NEWS APP
Christopher Carbone and the Fox News Associated Press contributed to this article. Follow James Rogers on Twitter @jamesjrogers
